Alzheimer’s drugs should be prescribed like statins to stave off dementia, one of Britain’s leading neuroscientists has said.

Meta-Description: Drugmaker AbbVie could be set up for a big year in 2025 after completing another successful clinical trial ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

According to NHS warnings, Ropinirole can cause patients to start binge eating, gambling and shopping uncontrollably, or have ...

The NHS has paid out tens of thousands to a man who developed an “uncontrollable” gambling problem after he was given a common Parkinson’s drug, The Independent can reveal Philip Stevens, a 66 year ...

A Penn Medicine-led consortium of radiology and chemistry researchers across the United States will advance imaging of ...

AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...

Why digital measurements startup Koneksa Health thinks it can help pharma measure if their drugs are effective in people with ...

Parkinson disease, stroke, and dementia were 2 to 3 times more prevalent among cases vs controls. This large population-based study has shown that several therapeutic groups, classes, subclasses, and ...

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

AbbVie has reported that the Phase III TEMPO-2 trial of tavapadon for early-stage Parkinson's disease met its primary endpoint.